Citations

Showing 10 of 108119 citations.

Risk of malignancy and outcomes of surgically resected presacral tailgut cysts: A current review of the Mayo Clinic experience
Broccard, Sacha P. , Mishra, Nitin , Davis, Peter , Maimone, Kristi L., Mathis, Kellie L. , Stocchi, Luca , Dozois, Eric J. , Merchea, Amit , Colibaseanu, Dorin T, Merchea, Amit , Colibaseanu, Dorin , Behm, Kevin T.

Mayo Clinic

Colorectal Disease | December 23, 2021 | Volume: 24 | Issue: 4 | Pages: 422-427

10.1111/codi.16030 | PMID 34941020 Get It

Abstract Aim The aim of this study was to describe the surgical management, outcomes and risk of malignancy of presacral tailgut cysts. Method A retrospective analysis of all patients who underwent resection of tailgut cyst at Mayo Clinic in Arizona, Florida and Minnesota between 2008 and 2020 was performed. Demographics, presentation, evaluation, surgical approach, postoperative complications, pathology and recurrence rates were reviewed. Results Seventy‐three patients were identified (81% female) with a mean age of 45 years. Thirty‐nine patients (53%) were symptomatic, most commonly with pelvic pain (26 patients). Digital rectal examination identified a palpable mass in 68%. Mean tumour size was 6 cm. Resection was primarily performed through a posterior approach (77%, n = 56), followed by a transabdominal approach (18%, n = 13) and a combined approach (5%, n = 4). Six patients underwent a minimally invasive resection (laparoscopic/robotic). Coccygectomy or distal sacrectomy was performed in 41 patients (56%). Complete resection was achieved in 94% of patients. Thirty‐day morbidity occurred in 18% and was most commonly wound related; there was no mortality. Malignancy was identified in six patients (8%). For the 30 patients with follow‐up greater than 1 year, the median follow‐up was 39 months (range 1.0–11.1 years). Local recurrence was identified in three patients and distant metastatic disease in one patient. Conclusion The rate of malignancy in presacral tailgut cysts based on this current review was 8%. Overall recurrence was 5% at a median of 24 months.
Peripheral Nerve Stimulation: The Evolution in Pain Medicine
D’Souza, Ryan S. , D'Souza, Ryan S , Abd-Elsayed, Alaa A

Mayo Clinic

Biomedicines | December 23, 2021 | Volume: 10 | Issue: 1 | Pages: 18

10.3390/biomedicines10010018 | PMID 35052698 Get It

Electrical stimulation of peripheral nerves has been utilized for a variety of indications for over five decades [...]
Identifying histopathologic features of erythema elevatum diutinum and granuloma faciale
Chukwuma, Olivia, Satcher, Kerrie G. , Kallis, Penelope , Vincek, Vladimir , Sokumbi, Olayemi , Satcher, Kerrie , Kallis, Penelope J , Motaparthi, Kiran , Frantz, Robert P.

Mayo Clinic

Journal of Cutaneous Pathology | December 23, 2021 | Volume: 49 | Issue: 3 | Pages: 323-326

10.1111/cup.14191 | PMID 34939211 Get It

Analysis of Operating Room Efficiency During Robot-Assisted Urologic Surgeries Utilizing Fixed (Nonprocedural) Operative Times
Geldmaker, Laura , Hasse, Christopher H., Baird, Bryce , Haehn, Daniela A. , Anyane-Yeboah, Abena N., Wieczorek, Mikolaj A. , Ball, Colleen T. , Dora, Chandler , Lyon, Timothy D. , Thiel, David D. , Geldmaker, Laura E, Baird, Bryce A, Dora, Chandler D , Geldmaker, Laura E , Lyon, Timothy D

Mayo Clinic

Journal of Endourology | December 23, 2021 | Volume: 36 | Issue: 5 | Pages: 654-660

10.1089/end.2021.0673 | PMID 34937418 Get It

Endoscopic Removal of an Eroded LINX ® Device Using a Mechanical Biliary Lithotriptor
Parker, Brett , Dinary, Fazel, Kumbhari, Vivek , Louie, Brian E. , Louie, Brian E

Mayo Clinic

Foregut: The Journal of the American Foregut Society | December 23, 2021 | Volume: 2 | Issue: 1 | Pages: 89-95

10.1177/26345161211048818 Get It

Background: Magnetic sphincter augmentation (MSA) via the surgical placement of a LINX ® device (LINX ® Reflux Management System, Torax Medical, Shoreview, MN, USA) is an increasingly performed minimally invasive outpatient anti-reflux procedure with a low erosion rate. The most common initial approach to eroded LINX ® devices is endoscopic removal. Often endoscopy centers do not have specialized devices to cut through the newer, more durable LINX ® systems. In this paper we describe a unique approach for removal of a LINX ® with intraluminal erosion using a commonly stocked mechanical biliary lithotripsy device. Case description: A 63-year-old male with a history of GERD and symptomatic type III paraesophageal hernia (PEH) underwent a robotic PEH repair with magnetic sphincter augmentation (1.5T, 17 bead) at an outside hospital. He developed an acute recurrence of his PEH, and subsequent upper endoscopy and contrast esophagram four weeks postoperatively revealed a gastric erosion of the LINX device, which had migrated 6 cm onto the stomach. Attempted endoscopic LINX ® removal using the OVESCO remove DC Cutter device was unsuccessful. Using principles of prior endoscopic bariatric lap band foreign body removal, the entire LINX ® device was successfully removed with the described biliary lithotriptor technique. Conclusion: Using a common biliary mechanical lithotriptor device and a guidewire to transect the newer 1.5T LINX ® Reflux Management System is a safe, effective and familiar technique for endoscopic removal of an eroded MSA device.
Effects of Adipose-Derived Biogenic Nanoparticle-Associated microRNA-451a on Toll-like Receptor 4-Induced Cytokines
Wang, Xinghua , Pham, Anthony , Lu, Kang , Walker, Sierra A. , Davidovich, Irina, Iannotta, Dalila , TerKonda, Sarvam P. , Talmon, Yeshayahu , Wolfram, Joy , Kang, Lu, Talmon, Yeshayahu , Wolfram, Joy , Kang, Lu, Shapiro, Shane A. , Pham, Si M.

Mayo Clinic

Pharmaceutics | December 23, 2021 | Volume: 14 | Issue: 1 | Pages: 16

10.3390/pharmaceutics14010016 | PMID 35056912 Get It

Extracellular vesicles (EVs) are cell-released nanoparticles that transfer biomolecular content between cells. Among EV-associated biomolecules, microRNAs (miRNAs/miRs) represent one of the most important modulators of signaling pathways in recipient cells. Previous studies have shown that EVs from adipose-derived mesenchymal stromal cells (MSCs) and adipose tissue modulate inflammatory pathways in macrophages. In this study, the effects of miRNAs that are abundant in adipose tissue EVs and other biogenic nanoparticles (BiNPs) were assessed in terms of altering Toll-like receptor 4 (TLR4)-induced cytokines. TLR-4 signaling in macrophages is often triggered by pathogen or damage-induced inflammation and is associated with several diseases. This study demonstrates that miR-451a, which is abundant in adipose tissue BiNPs, suppresses pro-inflammatory cytokines and increases anti-inflammatory cytokines associated with the TLR4 pathway. Therefore, miR-451a may be partially responsible for immunomodulatory effects of adipose tissue-derived BiNPs.
Research on Anal Squamous Cell Carcinoma
Hallemeier, Christopher L. , Jethwa, Krishan R. , Hallemeier, Christopher Leigh

Mayo Clinic

Cancers | December 23, 2021 | Volume: 14 | Issue: 1 | Pages: 42

10.3390/cancers14010042 | PMID 35008206 Get It

Anal canal and peri-anal squamous cell carcinomas (ASCCs) are relatively rare cancers that affect approximately 8000 patients per year in the United States [...]
Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor Responders
Lake, Douglas F. , Roeder, Alexa J. , González‐Moa, María J., Koehler, Megan , Kaleta, Erin, Vanderhoof, John , McKechnie, Davis, Forman, Jack, Edwards, Baylee A. , Svarovsky, Sergei, Jasbi, Paniz , Seit‐Nebi, Alim S.

Mayo Clinic

No container title available | December 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1168060/v1 Get It

Abstract Background While evaluating COVID-19 vaccine responses using a rapid neutralizing antibody (NAb) test, we observed that 25% of RNA vaccine recipients did not neutralize >50%. We termed this group “vaccine poor responders” (VPRs). The objective of this study was to determine if individuals who neutralized <50% would remain VPRs, or if a third dose would elicit high levels of NAbs. Methods 269 healthy individuals ranging in age from 19 to 80 (Average age = 51; 165 females and 104 males) who received either BNT162b2 (Pfizer) or mRNA1273 (Moderna) vaccines were evaluated. NAb levels were measured: i) 2-4 weeks after a second vaccine dose, ii) 2-4 months after the second dose, iii) within 1-2 weeks prior to a third dose and iv) 2-4 weeks after a third RNA vaccine dose. Results Analysis of vaccine recipients revealed that 25% did not neutralize above 50% (Median neutralization = 21%, titers <1:80) within a month after their second dose. Twenty-three of these VPRs obtained a third dose of either BNT162b2 or mRNA-1273 vaccine 1-8 months (average = 5 months) after their second dose. Within a month after their third dose, VPRs showed an average 20-fold increase in NAb levels (range: 46%-99%). Conclusions The results suggest that VPRs are not permanently poor responders; they can generate high NAb levels with an additional vaccine dose. Although it is not known what levels of NAbs protect from infection or disease, those in high-risk professions may wish to keep peripheral NAb levels high, limiting infection, and potential transmission.
Geriatric patients with esophageal motility disorders benefit more from minimally invasive peroral endoscopic myotomy: a multicenter study in Japan
Ujiie, Naoto , Sato, Hiroki , Tanaka, Shinwa , Shiwaku, Hironari , Shiota, Junya , Ogawa, Ryo , Yokomichi, Hiroshi , Kamei, Takashi , Inoue, Haruhiro , Fujiyoshi, Mary Raina Angeli

Mayo Clinic

Diseases of the Esophagus | December 22, 2021 | Volume: 35 | Issue: 6 | Pages: No page available

10.1093/dote/doab086 | PMID 34937083 Get It

Summary Geriatric patients with existing studies on the safety and efficacy of peroral endoscopic myotomy (POEM) for achalasia involve small sample sizes and single institutions. However, multi-center, large-scale data analyses are lacking. The study aimed to clarify the characteristics of geriatric patients with esophageal motility disorders (EMDs) and determine the procedure-related outcomes and clinical course following POEM. This cohort study included 2,735 patients with EMDs who were treated at seven Japanese facilities between 2010 and 2019. The patients’ characteristics and post-POEM clinical courses were compared between the geriatric (age ≥ 75 years; n = 321) and non-geriatric (age &lt; 75 years; n = 2,414) groups. Compared with the non-geriatric group, the geriatric group had higher American Society of Anesthesiologists physical status scores; more recurrent cases; lower incidence of chest pain; and higher incidence of type III achalasia, distal esophageal spasm, and Jackhammer esophagus. Furthermore, the incidence of sigmoid esophagus was higher, although esophageal dilation was not severe in this group. POEM was safe and effective for geriatric patients with treatment-naïve and recurrent EMDs. Furthermore, compared with the non-geriatric group, the geriatric group had lower post-POEM Eckardt scores, fewer complaints of refractory chest pain, and a lower incidence rate of post-POEM reflux esophagitis. Geriatric patients are characterized by worse clinical conditions, more spastic disorders, and greater disease progression of EMDs, which are also the indications for minimally invasive POEM. POEM is more beneficial in geriatric patients as it has lowering symptom scores and incidence rates of reflux esophagitis.
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes
Shah, Shailee , Paul, Pritikanta , Bryant, Sandra C. , Devine, Michelle F., Lennon, Vanda A. , Pittock, Sean J. , Dubey, Divyanshu , Paul, Pritikanta , Pittock, S J , Dubey, Divyanshu , Shah, Shailee , Flanagan, Eoin P. , Smith, Carin Y. , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | December 22, 2021 | Volume: 9 | Issue: 2 | Pages: No page available

10.1212/nxi.0000000000001124 | PMID 34937736 Get It